| Date | Time | Source | Headline | Symbol | Company |
| 09/09/2019 | 7:30AM | Business Wire | Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress... | NASDAQ:CELG | Celgene Corporation |
| 08/27/2019 | 3:02AM | Dow Jones News | Celgene, Bristol Clear Way For Merger -- WSJ | NASDAQ:CELG | Celgene Corporation |
| 08/26/2019 | 11:14AM | Dow Jones News | Amgen to Buy Celgene's Otezla for $13.4 Billion--Update | NASDAQ:CELG | Celgene Corporation |
| 08/26/2019 | 7:49AM | Dow Jones News | Amgen to Buy Celgene's Otezla for $13.4 Billion -- Update | NASDAQ:CELG | Celgene Corporation |
| 08/26/2019 | 7:31AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:CELG | Celgene Corporation |
| 08/26/2019 | 7:14AM | Dow Jones News | Amgen to Buy Celgene's Otezla for $13.4 Billion | NASDAQ:CELG | Celgene Corporation |
| 08/26/2019 | 6:30AM | PR Newswire (US) | Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefi... | NASDAQ:CELG | Celgene Corporation |
| 08/21/2019 | 8:45AM | InvestorWire | Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector | NASDAQ:CELG | Celgene Corporation |
| 08/16/2019 | 11:14AM | Dow Jones News | FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treatment | NASDAQ:CELG | Celgene Corporation |
| 08/16/2019 | 10:30AM | Business Wire | U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis | NASDAQ:CELG | Celgene Corporation |
| 08/05/2019 | 4:01PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:CELG | Celgene Corporation |
| 07/30/2019 | 4:12PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:CELG | Celgene Corporation |
| 07/30/2019 | 8:43AM | Dow Jones News | Second-Quarter Revenue at Celgene Surpasses Wall Street Targets | NASDAQ:CELG | Celgene Corporation |
| 07/30/2019 | 7:43AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:CELG | Celgene Corporation |
| 07/30/2019 | 7:30AM | Business Wire | Celgene Reports Second Quarter 2019 Operating and Financial Results | NASDAQ:CELG | Celgene Corporation |
| 07/29/2019 | 10:10AM | Business Wire | Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene | NASDAQ:CELG | Celgene Corporation |
| 07/26/2019 | 1:24PM | GlobeNewswire Inc. | Hach Rose Schirripa & Cheverie LLP Announces $55 Million Settlement in Antitrust Class Action Against Celgene | NASDAQ:CELG | Celgene Corporation |
| 07/25/2019 | 8:13AM | Dow Jones News | Bristol-Myers Squibb Reports Higher Profit, Revises Full-Year Outlook | NASDAQ:CELG | Celgene Corporation |
| 07/24/2019 | 7:30AM | Business Wire | Celgene & the Multiple Sclerosis Association of America Bring MS MindShift Initiative & “Brain Bulb” Hot Air Balloon to F... | NASDAQ:CELG | Celgene Corporation |
| 07/23/2019 | 4:00PM | GlobeNewswire Inc. | Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation | NASDAQ:CELG | Celgene Corporation |
| 07/19/2019 | 2:47PM | Dow Jones News | Celgene Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease | NASDAQ:CELG | Celgene Corporation |
| 07/19/2019 | 1:59PM | Business Wire | FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease | NASDAQ:CELG | Celgene Corporation |
| 07/16/2019 | 9:25AM | Dow Jones News | Zymeworks Says Celgene Selects Lead Oncology Therapeutic Candidate Under Collaboration | NASDAQ:CELG | Celgene Corporation |
| 06/26/2019 | 3:02AM | Dow Jones News | Facing Challenges, Firms Seek Deals -- WSJ | NASDAQ:CELG | Celgene Corporation |
| 06/25/2019 | 3:02AM | Dow Jones News | Celgene Deal Faces Antitrust Delays -- WSJ | NASDAQ:CELG | Celgene Corporation |
| 06/24/2019 | 3:30PM | Dow Jones News | Bristol-Myers, Celgene Shares Both Lower as Merger Faces Delays | NASDAQ:CELG | Celgene Corporation |
| 06/24/2019 | 2:36PM | Dow Jones News | Antitrust Concerns Delay Bristol-Myers' $74 Billion Merger With Celgene -- Update | NASDAQ:CELG | Celgene Corporation |
| 06/24/2019 | 12:19PM | Dow Jones News | Bristol-Myers' Celgene Deal Can Still Be a Winner -- Heard on the Street | NASDAQ:CELG | Celgene Corporation |
| 06/24/2019 | 9:37AM | Dow Jones News | Stocks to Watch: Caesars, Bristol-Myers, Carnival, FedEx, and More | NASDAQ:CELG | Celgene Corporation |
| 06/24/2019 | 8:53AM | Dow Jones News | Bristol-Myers to Shed Otezla, Carving Path for Celgene Deal | NASDAQ:CELG | Celgene Corporation |